Data highlights ability of Akari’s ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for driving hormone refractory prostate cancer progression ...

Dr. Sutera opened his talk by outlining that he would divide his presentation into three parts: first, defining MMAI; second, discussing its application in oligometastatic prostate cancer; and third, ...

Mdxhealth Announces Closing of Exosome Diagnostics Acquisition from Bio-Techne ...

Defense Secretary Pete Hegseth summoned hundreds of U.S. military officials to an in-person meeting Tuesday to announce ...

At ASTRO, Artera presented clinical validation data on its prostate cancer test in an Asian population,and showed how the test may complement gene expression-based approaches.

The company plans to launch in 2026 a program that will provide labs with scanners free of charge in exchange for volume-based payments for biomarker tests.

Imagine a future where the moment you’re born, a virtual avatar is created and steadily filled with personalised information ...

A UCLA study shows that a new treatment combining a radioactive drug with radiation therapy could help delay hormone therapy ...

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate ...

Only men with prostate tumors of the luminal B subtype benefited from adding apalutamide to salvage radiation in the phase 2 ...

A genetic test could guide the use of hormone therapy for men with recurrent prostate cancer after surgery, according to data ...

The PRIME trial tested whether the dynamic contrast enhancement sequence in multiparametric MRI is truly necessary to improve significant prostate cancer ...